5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 1 points (-0.0%) at 13,971 as of Friday, Feb. 15, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,429 issues advancing vs. 1,408 declining with 163 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Agilent Technologies ( A), down 3.8%, Dr. Reddy Laboratories ( RDY), down 2.6%, Stryker Corporation ( SYK), down 1.0% and Thermo Fisher Scientific ( TMO), down 1.0%. Top gainers within the sector include Pharmacyclics Incorporated ( PCYC), up 5.1%, Biogen Idec ( BIIB), up 2.4%, Shire ( SHPG), up 2.3%, Novartis ( NVS), up 0.7% and AstraZeneca ( AZN), up 0.6%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. DaVita HealthCare Partners ( DVA) is one of the companies pushing the Health Care sector lower today. As of noon trading, DaVita HealthCare Partners is down $2.17 (-1.8%) to $117.04 on average volume Thus far, 442,845 shares of DaVita HealthCare Partners exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $116.01-$118.50 after having opened the day at $118.47 as compared to the previous trading day's close of $119.21.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure, or end stage renal disease (ESRD) in the United States. DaVita HealthCare Partners has a market cap of $11.3 billion and is part of the health services industry. The company has a P/E ratio of 21.5, above the S&P 500 P/E ratio of 17.7. Shares are up 7.4% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, revenue growth, notable return on equity and growth in earnings per share. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full DaVita HealthCare Partners Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Blue Apron, Philip Morris, Honeywell, Becton Dickinson: 'Mad Money' Lightning Round

Buy These High-Octane Stocks on a Dip: Cramer's 'Mad Money' Recap (Monday 8/7/17)

Buy It Like Buffett -- or Better

Buy It Like Buffett -- or Better